Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (876)	12/22/1998 3:09:00 AM
From: Henry Niman	Respond to of 965

Peter, I think that the CNTO move early Monday morning was more related to the AMGN news, which came out after the close on Friday, than anything else. The AMGN news focused attention on Biotechs, particularly those who make money.

To: Biomaven who wrote (876)	1/12/1999 6:13:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 965

Today's WSJ reviews earnings for the larger profitable Biotechs. New products of course played a major role in the increased earnings of 4Q. The companies and products covered include AMGN (NESP), BGEN (Avonex), CHIR (Proleukin), CNTO (Reopro/Remicade), GNE (Herceptin), GENZ (Cerezyme/Ceredase), IMNX (Enbrel), AGPH (Viracept). Details linked to the Biotech Boom table (which also has a list of Biotechs presenting at this week's H&Q Healthcare Conference) at biocognizance.com